SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, Bertrand Mennecier, Didier Debieuvre, David Planchard, Gérard Zalcman, Denis Moro-Sibilot, Jacques Cadranel, Fabrice Barlési, ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?, Expert Review of Anticancer Therapy, 2015, 15, 2, 225

    CrossRef

  2. 2
    Alastair Greystoke, Anshuman Chaturvedi, An introduction to stratified medicine, Drug Discovery Today, 2015, 20, 12, 1409

    CrossRef

  3. 3
    Herbert H Loong, Kevin Mok, Linda KS Leung, Tony SK Mok, Crizotinib in the management of advanced-stage non-small-cell lung cancer, Future Oncology, 2015, 11, 5, 735

    CrossRef

  4. 4
    Federico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, Ekaterini Boleti, Enriqueta Felip, Harry J.M. Groen, Paul Germonpré, Peter Meldgaard, Edurne Arriola, Nicola Steele, Jesme Fox, Patrick Schnell, Arne Engelsberg, Jürgen Wolf, Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus, Lung Cancer, 2015, 87, 2, 89

    CrossRef

  5. 5
    Nuria Kotecki, Nicolas Penel, Ahmad Awada, Metabolic disorders associated with the use of targeted cancer therapies, Current Opinion in Oncology, 2015, 27, 3, 258

    CrossRef

  6. 6
    Assunta Sgambato, Francesca Casaluce, Antonio Rossi, Paolo Maione, Paola Claudia Sacco, Fortunato Ciardiello, Cesare Gridelli, The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes, Clinical Investigation, 2015, 5, 2, 217

    CrossRef

  7. 7
    Nisha A Mohindra, Jyoti D Patel, Towards manageable toxicities from targeted lung cancer treatment, Lung Cancer Management, 2015, 4, 6, 279

    CrossRef

  8. 8
    Paolo Bironzo, Teresa Mele, Silvia Novello, Lung Cancer, 2015,

    CrossRef

  9. 9
    Conor E. Steuer, Suresh S. Ramalingam, ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options, Cancer, 2014, 120, 16
  10. 10
    D. Ross Camidge, Evelyn M. Brosnan, Chamath DeSilva, Phillip J. Koo, Michel Chonchol, Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate, Journal of Thoracic Oncology, 2014, 9, 11, 1634

    CrossRef

  11. 11
    Lorenza Landi, Federico Cappuzzo, Management of NSCLC: focus on crizotinib, Expert Opinion on Pharmacotherapy, 2014, 15, 17, 2587

    CrossRef

  12. 12
    Eamon M. Berge, Robert C. Doebele, Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor, Seminars in Oncology, 2014, 41, 1, 110

    CrossRef

  13. 13
    Rony Dev, Eduardo Bruera, Egidio Del Fabbro, When and When Not To Use Testosterone for Palliation in Cancer Care, Current Oncology Reports, 2014, 16, 4

    CrossRef

  14. 14
    James E. Frampton, Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer, Drugs, 2013, 73, 18, 2031

    CrossRef